Loading...
OTCM
SHTDY
Market cap7.46bUSD
Jul 11, Last price  
11.94USD
1D
0.59%
1Q
5.48%
Jan 2017
-41.76%
IPO
-45.83%
Name

Sinopharm Group Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
37.74
P/S
0.46
EPS
2.27
Div Yield, %
5.03%
Shrs. gr., 5y
0.96%
Rev. gr., 5y
6.57%
Revenues
584.51b
-2.02%
23,736,642,00031,110,214,00038,187,433,00047,045,853,00069,233,669,000102,224,807,000135,786,836,000166,866,146,000200,131,261,000228,672,929,000258,117,225,000277,028,977,000344,525,821,000425,272,726,000456,414,611,000521,051,235,000552,147,550,000596,569,565,000584,507,930,000
Net income
7.05b
-22.14%
182,448,000535,949,000818,103,000845,819,0001,208,751,0001,560,606,0001,973,823,0002,250,002,0002,874,823,0003,760,649,0004,647,344,0007,868,176,0009,404,484,00010,620,072,00012,097,291,00013,064,773,00014,345,442,0009,053,760,0007,049,683,000
CFO
11.55b
-32.77%
638,439,000441,180,000653,849,0001,011,505,0001,202,537,0001,019,269,0004,017,209,0004,941,294,0005,560,835,00013,412,333,0009,257,964,0001,667,345,0003,653,739,00018,777,096,00011,154,609,0009,308,085,00020,963,787,00017,173,030,00011,546,010,000
Dividend
Jun 18, 20240.601 USD/sh
Earnings
Aug 21, 2025

Profile

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
URL
https://www.sinopharmholding.com/
IPO date
Sep 23, 2009
Employees
113,362
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
584,507,930
-2.02%
596,569,565
8.05%
552,147,550
5.97%
Cost of revenue
565,824,723
574,207,650
529,616,610
Unusual Expense (Income)
NOPBT
18,683,207
22,361,915
22,530,940
NOPBT Margin
3.20%
3.75%
4.08%
Operating Taxes
3,577,305
4,502,309
4,218,377
Tax Rate
19.15%
20.13%
18.72%
NOPAT
15,105,902
17,859,606
18,312,563
Net income
7,049,683
-22.14%
9,053,760
-36.89%
14,345,442
9.80%
Dividends
(2,558,837)
(2,340,492)
Dividend yield
4.01%
3.78%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
64,489,623
56,526,974
54,633,193
Long-term debt
16,916,366
22,472,244
19,799,500
Deferred revenue
412,973
Other long-term liabilities
3,871,843
4,330,584
3,436,277
Net debt
16,198,331
4,639,447
9,370,609
Cash flow
Cash from operating activities
11,546,010
17,173,030
20,963,787
CAPEX
(2,460,690)
(1,959,570)
(2,417,529)
Cash from investing activities
(3,750,920)
(944,535)
(3,589,622)
Cash from financing activities
(17,285,030)
(7,643,970)
(5,693,481)
FCF
(825,946)
8,557,774
16,237,549
Balance
Cash
54,313,517
63,809,085
55,222,122
Long term investments
10,894,141
10,550,686
9,839,962
Excess cash
35,982,262
44,531,293
37,454,706
Stockholders' equity
126,691,140
98,267,244
87,991,373
Invested Capital
170,963,018
153,899,888
142,775,244
ROIC
9.30%
12.04%
12.86%
ROCE
9.03%
11.27%
12.44%
EV
Common stock shares outstanding
3,116,818
3,116,818
3,120,656
Price
21.30
4.16%
20.45
3.07%
19.84
16.98%
Market cap
66,388,223
4.16%
63,738,928
2.95%
61,913,815
17.34%
EV
130,390,061
114,114,903
117,675,632
EBITDA
23,416,899
26,792,163
26,695,959
EV/EBITDA
5.57
4.26
4.41
Interest
2,956,587
3,520,326
Interest/NOPBT
13.22%
15.62%